Materiały źródłowe

• #1 Macular Degeneration: Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/15246-macular-degeneration

  Macular degeneration is primarily an age-related retinal condition. There are two types of macular degeneration wet and dry. There are treatments, but there isnt a cure. […] There are two types of macular degeneration: dry and wet. […] Wet (exudative) macular degeneration occurs when abnormal blood vessels develop under your retina and macula. […] About 10% of people with macular degeneration have the wet form. This type is more severe. It can quickly lead to total loss of central vision. […] Theres no cure for macular degeneration. Starting treatments early can slow the progression of the disease and make symptoms less severe. […] Depending on the disease type, treatments include nutritional supplements, medications, photodynamic therapy (PDT) and laser therapy. […] There are drugs that treat but dont cure wet AMD. They include anti-vascular endothelial growth factor (anti-VEGF) injections.

• #2 Wet Macular Degeneration | Signs, Symptoms, and Treatments

  https://www.macular.org/about-macular-degeneration/wet-macular-degeneration

  Approximately 10-15% of the cases of macular degeneration are the wet (exudative) type, sometimes also referred to at neovascular macular degeneration or nAMD. […] In the wet type of macular degeneration, abnormal blood vessels (known as choroidal neovascularization or CNV) grow under the retina and macula. […] Early intervention of any bleeding offers the best chance of preserving vision. […] Unlike Dry AMD which can be slowed in many patients through lifestyle changes, supplements, and an AMD Diet, wet AMD cannot be slowed by natural remedies and needs to be treated as early as possible by a retina specialist. […] Early, and sustained treatment has been shown to be the best course of action to preserve as much vision as possible for as long as possible if you have developed wet macular degeneration.

• #3 Wet macular degeneration – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113

  Macular degeneration, wet care at Mayo Clinic […] To diagnose wet macular degeneration, an eye doctor typically reviews medical and family history and does a complete eye exam. […] Treatments are available that may help slow disease progression and preserve existing vision. If started early enough, treatment may recover some lost vision. […] Some medicines, called anti-VEGF drugs, may help stop the growth of new blood vessels. These medicines block the effects of growth signals the body sends to generate new blood vessels. They are considered the first line of treatment for all stages of wet macular degeneration. […] An eye doctor injects these medicines into the affected eye. Shots may be needed every 4 to 6 weeks to maintain the beneficial effect of the medicine. In some instances, vision may be partially recovered as the blood vessels shrink and the body absorbs the fluid under the retina.

• #4 Wet Macular Degeneration: Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/wet-macular-degeneration

  When you have WMD, new vessels grow and disrupt existing retinal tissue, causing damage and vision loss. The leaked blood can also cause scar tissue to form, further distorting and damaging the macula. […] Over time, the leaked blood and scar tissue can cause permanent vision loss. However, early detection and treatment can prevent that kind of permanent damage or stop it from further damaging your vision. If you notice vision changes that could be WMD, you need to see an ophthalmologist as soon as possible. […] Wet macular degeneration is very treatable if detected early enough. There are two main ways to treat WMD: medications and laser procedures. […] Medication treatments involve blocking vascular endothelial growth factor (VEGF), a protein your body uses for growing new blood vessels. Blocking VEGF stops the formation of new blood vessels. The medications that can do this are given via an injection into your eye.

• #5 Treatment for Age-Related Macular Degeneration | Macular Disease Foundation Australia

  https://www.mdfoundation.com.au/about-macular-disease/age-related-macular-degeneration/amd-treatment/

  Anti-VEGF eye injections can save the sight of people with wet AMD. […] There is effective, sight-saving treatment for the most aggressive form of the disease: wet (neovascular) age-related macular degeneration. […] There is highly effective treatment for wet (neovascular) AMD. This is most commonly delivered in the form of regular injections to the eye. […] Anti-VEGF medication can block the activity of this VEGF protein, thereby stopping the growth of abnormal blood vessels and fluid leakage. […] Standard treatment for wet AMD involves an injection of anti-VEGF medication into the clear, jelly-like substance (called the vitreous) inside the eye. […] Eye injections are also called intravitreal injections or IVI. […] For most people, treatment usually begins with injections at monthly intervals. Your injection schedule will depend on how you respond to the treatment.

• #6 Treatments for Wet AMD (Advanced Neovascular AMD) | National Eye Institute

  https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration/treatments-wet-amd-advanced-neovascular-amd

  Age-related macular degeneration (AMD) is an eye disease that can blur the center of your vision. Wet AMD (also called advanced neovascular AMD) is a serious type of late AMD. It happens when a protein called vascular endothelial growth factor (VEGF) makes abnormal blood vessels grow in the wrong place in the back of your eye. […] The good news is that there are effective treatments for wet AMD. […] There are 2 treatment options that can slow down or stop vision loss from wet AMD: Anti-VEGF injections and Photodynamic therapy (PDT). […] The most common treatment doctors use to slow vision loss from wet AMD is called anti-VEGF injections. These medicines help stop bleeding and leaking from blood vessels in the back of your eye. Most people with wet AMD will get anti-VEGF injections as their only treatment. […] Photodynamic therapy (PDT) is a much less common treatment for wet AMD that doctors sometimes use along with anti-VEGF injections.

• #7

  https://www.aao.org/eye-health/diseases/amd-macular-degeneration

  Wet Age-Related Macular Degeneration is when new, abnormal blood vessels grow under the retina. These vessels may leak blood or other fluids, causing scarring of the macula. You lose vision faster with wet AMD than with dry AMD. […] To help treat wet AMD, there are medications called anti-VEGF drugs. Anti-VEGF treatment helps reduce the number of abnormal blood vessels in your retina. It also slows any leaking from blood vessels. This medicine is delivered to your eye through a very slender needle. […] Laser surgery may also be used to treat some types of wet AMD. Your eye surgeon shines a laser light beam on the abnormal blood vessels. This reduces the number of vessels and slows their leaking.

• #8 Exudative (Wet) Age-Related Macular Degeneration (AMD) Medication: Phototherapy Agents, Anti-VEGF Therapy, Ophthalmics, Complement Inhibitors

  https://emedicine.medscape.com/article/1226030-medication

  Intravitreal injections with vascular endothelial growth factors (VEGF) inhibitors (eg, aflibercept, ranibizumab, brolucizumab, faricimab) are used to reduce the progression of exudative AMD. […] Complement inhibitors, such as pegcetacoplan intravitreal (Syfovre) and avacincaptad pegol intravitreal (Izervay), are indicated for geographic atrophy (GA) secondary to age-related macular degeneration. […] This treatment reduces the risk of visual loss similar to that seen with PDT. […] Aflibercept intravitreal (Eylea, Eylea HD, Opuviz, Yesafili) is indicated for neovascular (wet) age-related macular degeneration (AMD). […] Brolucizumab intravitreal (Beovu, brolucizumab-dbll) is indicated for adults with nAMD. […] Ranibizumab intravitreal injection (Lucentis, Byooviz, Cimerli) is indicated for neovascular (wet) AMD.

• #9 Treatments for Patients with Wet Age-Related Macular Degeneration | Hull University Teaching Hospitals NHS Trust

  https://www.hey.nhs.uk/patient-leaflet/treatments-patients-wet-age-related-macular-degeneration/

  Anti VEGF injection treatment has the following potential benefits: 90 to 95% chance of avoiding severe loss of central vision in the eye treated. 70% chance of keeping the vision as it was when treatment began OR of a small improvement in vision. 30 to 40% chance of a big improvement in vision i.e. of regaining a large amount of the vision that has been lost. […] Unfortunately, there is no research evidence that injection treatment will work once vision drops in the eye below a certain level. […] Avastin (Bevacizumab) is an anti VEGF agent and has been shown to have effects similar to Lucentis and Eylea but is not licensed for use in the eye and hence it is not used in this hospital to treat Wet AMD. […] Photodynamic therapy (PDT) was the standard treatment for Wet AMD before anti VEGF injections became available.

• #10 Medication for Macular Degeneration | NYU Langone Health

  https://nyulangone.org/conditions/macular-degeneration/treatments/medication-for-macular-degeneration

  Although there are currently no medications available to manage dry macular degeneration, NYU Langone ophthalmologists can prescribe medications to help prevent the wet form of macular degeneration from progressing. […] These medications are given as intravitreal injections, which means they are injected into the eye. They are so effective that in many people some vision can be restored after consistent treatment. […] In wet macular degeneration, abnormal blood vessels grow underneath the macula, the part of the eyes retina that enables you to see objects directly in front of you. […] However, if medication helps the blood vessels stop leaking, the progression of the disease may be halted. […] A new class of medications, known as anti-vascular endothelial growth factor therapy, is very effective in stopping the growth of new abnormal blood vessels in the eye. […] In most people who are given anti-vascular endothelial growth factor therapy, wet macular degeneration stops progressing. Vision loss is halted in about 90 percent of people, and up to one-third experience improvements in vision after treatment is complete.

• #11 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  Avastin (bevacizumab) may be used in some circumstances. But Avastin is an anti-VEGF drug that was developed to treat cancer and is not licensed for use in the eye. It is still safe and effective to treat wet AMD. […] Lucentis (ranibizumab) was the first anti-VEGF to be licensed for wet AMD. Patients may need to go for treatment every four weeks with this medication. […] Eylea (aflibercept) is longer lasting in the eye compared to Lucentis, on average a patient may only need to attend treatment every eight weeks. […] Beovu (brolucizumab) is longer-acting than the previous treatments, and needs to be injected only around every 12 weeks. […] Vabysmo (Faricimab) is the most recently approved medication for treatment of wet AMD. It is the first dual action drug and tackles two biological pathways involved in blood vessel growth, VEFG and Ang-2. It is also longer acting and patients may be able to go 12 or 16 weeks between injections.

• #12 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  Avastin (bevacizumab) may be used in some circumstances. But Avastin is an anti-VEGF drug that was developed to treat cancer and is not licensed for use in the eye. It is still safe and effective to treat wet AMD. […] Lucentis (ranibizumab) was the first anti-VEGF to be licensed for wet AMD. Patients may need to go for treatment every four weeks with this medication. […] Eylea (aflibercept) is longer lasting in the eye compared to Lucentis, on average a patient may only need to attend treatment every eight weeks. […] Beovu (brolucizumab) is longer-acting than the previous treatments, and needs to be injected only around every 12 weeks. […] Vabysmo (Faricimab) is the most recently approved medication for treatment of wet AMD. It is the first dual action drug and tackles two biological pathways involved in blood vessel growth, VEFG and Ang-2. It is also longer acting and patients may be able to go 12 or 16 weeks between injections.

• #13 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  Avastin (bevacizumab) may be used in some circumstances. But Avastin is an anti-VEGF drug that was developed to treat cancer and is not licensed for use in the eye. It is still safe and effective to treat wet AMD. […] Lucentis (ranibizumab) was the first anti-VEGF to be licensed for wet AMD. Patients may need to go for treatment every four weeks with this medication. […] Eylea (aflibercept) is longer lasting in the eye compared to Lucentis, on average a patient may only need to attend treatment every eight weeks. […] Beovu (brolucizumab) is longer-acting than the previous treatments, and needs to be injected only around every 12 weeks. […] Vabysmo (Faricimab) is the most recently approved medication for treatment of wet AMD. It is the first dual action drug and tackles two biological pathways involved in blood vessel growth, VEFG and Ang-2. It is also longer acting and patients may be able to go 12 or 16 weeks between injections.

• #14 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  Avastin (bevacizumab) may be used in some circumstances. But Avastin is an anti-VEGF drug that was developed to treat cancer and is not licensed for use in the eye. It is still safe and effective to treat wet AMD. […] Lucentis (ranibizumab) was the first anti-VEGF to be licensed for wet AMD. Patients may need to go for treatment every four weeks with this medication. […] Eylea (aflibercept) is longer lasting in the eye compared to Lucentis, on average a patient may only need to attend treatment every eight weeks. […] Beovu (brolucizumab) is longer-acting than the previous treatments, and needs to be injected only around every 12 weeks. […] Vabysmo (Faricimab) is the most recently approved medication for treatment of wet AMD. It is the first dual action drug and tackles two biological pathways involved in blood vessel growth, VEFG and Ang-2. It is also longer acting and patients may be able to go 12 or 16 weeks between injections.

• #15 VABYSMO™ (faricimab-svoa) | Wet AMD, DME and RVO Treatment

  https://www.vabysmo.com/

  VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). […] Clinical studies showed people on VABYSMO gained vision on an eye chart (6 letters on average), similar to those on aflibercept 2 mg through year 1. […] VABYSMO is thought to block the VEGF and Ang-2 proteins. […] In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. […] Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO.

• #16 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  Avastin (bevacizumab) may be used in some circumstances. But Avastin is an anti-VEGF drug that was developed to treat cancer and is not licensed for use in the eye. It is still safe and effective to treat wet AMD. […] Lucentis (ranibizumab) was the first anti-VEGF to be licensed for wet AMD. Patients may need to go for treatment every four weeks with this medication. […] Eylea (aflibercept) is longer lasting in the eye compared to Lucentis, on average a patient may only need to attend treatment every eight weeks. […] Beovu (brolucizumab) is longer-acting than the previous treatments, and needs to be injected only around every 12 weeks. […] Vabysmo (Faricimab) is the most recently approved medication for treatment of wet AMD. It is the first dual action drug and tackles two biological pathways involved in blood vessel growth, VEFG and Ang-2. It is also longer acting and patients may be able to go 12 or 16 weeks between injections.

• #17 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  New forms of anti-VEGF drugs are now available to treat wet AMD, called biosimilars. The first to become available is Ongavia, a biosimilar to ranibizumab. […] A biosimilar is a medicine developed to be highly similar to an existing biological medicine. Biosimilars might vary slightly from the original brand of medicine, but they work in the same way and they are equally safe and effective. […] Injections do not work if there is already longstanding damage to the macula. Around one in 10 people with wet AMD do not respond to treatment. […] There are two main reasons why patients who previously responded well to treatment may stop injections. The first is if someones macular has too much damage caused by the condition. This means a person has lost the majority of their central vision in that eye and therefore injections are no longer effective and it is in the patients best interest that treatment is stopped.

• #18 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  All anti-VEGF drugs need to be delivered directly into the eye. […] The current method is injections, however new methods are being delivered. […] In accordance with NICE AMD guidelines, all patients receive a standard loading dosage at the start of their injection treatment: normally three or more consecutive monthly injections. After this initial phase there are a number of treatment regimens that an ophthalmologist can choose. Each regimen has a subtle difference in the frequency of appointments. They also vary as to whether or not you have an injection at every appointment. The ophthalmologist will tailor treatment to individual patients and how their disease is responding to treatment. […] There are a few different medications used to treat wet AMD. They all are effective in treating the eye. The main difference between them is how long they last in the eye. Not everyone responds well to every medication, hospitals will treat a patient with the most suitable medication for the patients needs.

• #19 Wet AMD | Wills Eye Hospital

  https://www.willseye.org/wet-amd/

  In 2006, the FDA approved Lucentis (ranibizumab) for the treatment of wet AMD. This was the first treatment shown to improve vision in many people with wet AMD. […] Lucentis is administered in the office by an intraocular injection and typically dosed monthly for the first few treatments. […] Treatment will continue to some degree on an indefinite basis in most patients depending on the nature of the wet AMD and response to treatment, although the frequency and total number of injections may vary considerably among patients. […] Avastin is another drug used to treat wet AMD. […] Eylea was approved in November 2011 by the FDA to treat wet AMD. […] Beovu was FDA-approved in 2019 for the treatment of wet AMD. […] Macugen is a growth inhibiting drug that blocks VEGF to some degree and can also slow the growth of choroidal neovascularization and to reduce leakage in the macula.

• #20 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  Avastin (bevacizumab) may be used in some circumstances. But Avastin is an anti-VEGF drug that was developed to treat cancer and is not licensed for use in the eye. It is still safe and effective to treat wet AMD. […] Lucentis (ranibizumab) was the first anti-VEGF to be licensed for wet AMD. Patients may need to go for treatment every four weeks with this medication. […] Eylea (aflibercept) is longer lasting in the eye compared to Lucentis, on average a patient may only need to attend treatment every eight weeks. […] Beovu (brolucizumab) is longer-acting than the previous treatments, and needs to be injected only around every 12 weeks. […] Vabysmo (Faricimab) is the most recently approved medication for treatment of wet AMD. It is the first dual action drug and tackles two biological pathways involved in blood vessel growth, VEFG and Ang-2. It is also longer acting and patients may be able to go 12 or 16 weeks between injections.

• #21 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden

  https://www.ajmc.com/view/wet-agerelated-macular-degeneration-treatment-advances-to-reduce-the-injection-burden

  The goals of anti-VEGF therapy in neovascular AMD are to achieve excellent functional visual acuity and maintain a dry macula on clinical and OCT examination. This may require an individualized approach because AMD is a heterogenous disease. […] Two approaches—treat-and-extend (TE) and pro re nata (PRN; as needed)—have been used to reduce the injection burden in stable, nonexudative patients with neovascular AMD. The TE regimen gradually extends the dosing interval in 2-week increments to a maximum interval of 12 to 16 weeks. If disease activity is observed, then the treatment interval is reduced, often in 2-week increments but this varies with patient treatment factors. […] A robust pipeline of investigational drugs for neovascular AMD is expected to extend the dosing interval beyond that of currently available agents. Agents that are expected to reach the market within the next 3 years include abicipar pegol and faricimab, as well as the ranibizumab port system for extended-release drug delivery. […] Gene therapy could be another option for addressing the anti-VEGF injection burden. Initial clinical data for gene therapy have generated cautious excitement about its potential to substantially reduce the treatment burden in neovascular AMD. The technology uses a viral vector to insert the DNA coding sequence for an anti-VEGF agent into retinal cells that then act like anti-VEGF factories.

• #22 Wet macular degeneration – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113

  Photodynamic therapy. This procedure is a possible treatment for the irregular blood vessel growth in wet macular degeneration. However, it is much less common than treatment with anti-VEGF shots. […] Photodynamic therapy may improve vision and reduce the rate of vision loss. Repeated treatments may be needed over time, as the treated blood vessels may reopen. […] Photocoagulation. During photocoagulation therapy, an eye doctor uses a high-energy laser beam to seal problem blood vessels under the macula. This procedure helps stop the vessels from bleeding, with the aim of minimizing further damage to the macula. […] Low vision rehabilitation. Age-related macular degeneration doesn’t affect side vision and typically doesn’t cause total blindness. But it can reduce or eliminate central vision. You need central vision to read, drive and recognize people’s faces. […] Macular degeneration, wet care at Mayo Clinic […] Treatments for wet macular degeneration […] Photodynamic therapy.

• #23

  https://myhealth.alberta.ca/Health/pages/conditions.aspx?hwid=rt1252

  Photodynamic therapy (PDT) is a treatment for wet age-related macular degeneration (wet AMD). […] Photodynamic therapy may be recommended if you can’t have injections of medicines to treat your AMD or if these injections don’t work. […] The main treatment for wet AMD is injections of anti-VEGF medicines into the eye. Photodynamic therapy is not usually recommended. But when anti-VEGF injections can’t be used or don’t work, photodynamic therapy is one option that may be recommended. […] By limiting the growth of abnormal blood vessels under the macula, photodynamic therapy may help prevent the progression of wet AMD. It does not restore vision to eyes that have already been damaged. But it may help prevent further damage to the retina and further vision loss. […] PDT can lower the risk of severe vision loss by reducing the growth of and leakage from abnormal blood vessels under the retina. […] The effect of PDT in slowing the progress of AMD is often temporary, and the abnormal blood vessels begin leaking again after about 3 months. Most people need multiple treatments to get the full benefits of the therapy.

• #24 Photodynamic Therapy for Age-Related Macular Degeneration Information

  https://www.columbiadoctors.org/health-library/article/photodynamic-therapy-age-related-macular-degeneration/

  Photodynamic therapy (PDT) is a treatment for wet age-related macular degeneration (wet AMD). It is not used to treat dry AMD. […] Photodynamic therapy may be recommended if you can’t have injections of medicines to treat your AMD or if these injections don’t work. […] By limiting the growth of abnormal blood vessels under the macula, photodynamic therapy may help prevent the progression of wet AMD. It does not restore vision to eyes that have already been damaged. But it may help prevent further damage to the retina and further vision loss. […] PDT can lower the risk of severe vision loss by reducing the growth of and leakage from abnormal blood vessels under the retina. […] The effect of PDT in slowing the progress of AMD is often temporary, and the abnormal blood vessels begin leaking again after about 3 months. Most people need multiple treatments to get the full benefits of the therapy. […] A severe loss in visual clarity happens to some people who are treated with PDT. In some cases, vision partially recovers. […] Other side effects that may occur with PDT include: Temporary visual disturbances (abnormal vision, decreased vision, defects in the visual field).

• #25

  https://myhealth.alberta.ca/Health/pages/conditions.aspx?hwid=rt1252

  Photodynamic therapy (PDT) is a treatment for wet age-related macular degeneration (wet AMD). […] Photodynamic therapy may be recommended if you can’t have injections of medicines to treat your AMD or if these injections don’t work. […] The main treatment for wet AMD is injections of anti-VEGF medicines into the eye. Photodynamic therapy is not usually recommended. But when anti-VEGF injections can’t be used or don’t work, photodynamic therapy is one option that may be recommended. […] By limiting the growth of abnormal blood vessels under the macula, photodynamic therapy may help prevent the progression of wet AMD. It does not restore vision to eyes that have already been damaged. But it may help prevent further damage to the retina and further vision loss. […] PDT can lower the risk of severe vision loss by reducing the growth of and leakage from abnormal blood vessels under the retina. […] The effect of PDT in slowing the progress of AMD is often temporary, and the abnormal blood vessels begin leaking again after about 3 months. Most people need multiple treatments to get the full benefits of the therapy.

• #26 General 3 — Macular Degeneration New Zealand

  https://www.mdnz.org.nz/treatment

  Several anti-VEGF drugs are in use, namely Bevacizumab (Avastin), Aflibercept (Eylea) and Ranibizumab (Lucentis). […] Bevacizumab was primarily developed, tested and approved to decrease new blood vessel growth associated with cancer. It is highly effective and used worldwide for treating wet macular degeneration. […] Aflibercept is now the second-line agent for the treatment of wet macular degeneration and is registered for use in the eye, and funded by Pharmac but with availability restricted. […] Ranibizumab is very similar to bevacizumab. […] This is a 2-step process combining a light-activated drug called Visudyne (verteporfin) with light from a cold laser directed onto the abnormal area of retina. […] Several treatments are needed to keep the leaking blood vessels closed and stop the progression of wet macular degeneration. […] Unlike anti-VEGF drugs with which the vision is usually maintained, patients undergoing PDT continue to lose vision in the first 6 months. […] Laser photocoagulation is only used for a small percentage of patients with wet macular degeneration.

• #27

  https://myhealth.alberta.ca/Health/pages/conditions.aspx?hwid=rt1252

  Photodynamic therapy (PDT) is a treatment for wet age-related macular degeneration (wet AMD). […] Photodynamic therapy may be recommended if you can’t have injections of medicines to treat your AMD or if these injections don’t work. […] The main treatment for wet AMD is injections of anti-VEGF medicines into the eye. Photodynamic therapy is not usually recommended. But when anti-VEGF injections can’t be used or don’t work, photodynamic therapy is one option that may be recommended. […] By limiting the growth of abnormal blood vessels under the macula, photodynamic therapy may help prevent the progression of wet AMD. It does not restore vision to eyes that have already been damaged. But it may help prevent further damage to the retina and further vision loss. […] PDT can lower the risk of severe vision loss by reducing the growth of and leakage from abnormal blood vessels under the retina. […] The effect of PDT in slowing the progress of AMD is often temporary, and the abnormal blood vessels begin leaking again after about 3 months. Most people need multiple treatments to get the full benefits of the therapy.

• #28 Diagnosis and Treatment – Moorfields Private

  https://www.moorfields.nhs.uk/private/eye-conditions-and-treatments/age-related-macular-degeneration-amd/diagnosis-and-treatment

  Photodynamic therapy (PDT) is sometimes added to anti-VEGF injections. […] Anti-VEGF drugs like ranibizumab (Lucentis) and bevacizumab (Avastin) are injected into the eye to treat conditions where abnormal blood vessels leak fluid under the retina at the back of the eye. […] The injections aim to stop the blood vessels from growing and leaking, and to preserve central vision. This treatment is highly effective for many macular degeneration patients. […] Anti-VEGF medicines stop the abnormal blood vessels growing, then leaking and bleeding under the retina. This prevents or limits damage to the retinal light receptors and loss of central vision. These medicines are effective in preventing further central vision loss in up to 90% of treated eyes. […] Your ophthalmologist will advise if the treatment is appropriate for you and which anti-VEGF medicine will be used. Only patients with active leaking of blood and fluid can benefit from it. […] We provide treatment for AMD in several of our locations so that patients can get their care closer to home.

• #29 Macular Degeneration: Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/15246-macular-degeneration

  During photodynamic therapy (PDT), your eye care specialist uses a combination of an injectable light-sensitive drug and a laser to destroy extra blood vessels in your eye. […] During this treatment, your provider will use a laser to seal and destroy the leaking blood vessels. […] Treatments for wet AMD carry some risk of complications, including: Eye infection, Retinal detachment, Structural eye damage, Faster onset of cataracts, Severe vision loss. […] Age-related macular degeneration (AMD) is the leading cause of vision loss in older adults. […] Wet macular degeneration can cause rapid vision loss and may lead to legal blindness. Your eye care provider can offer treatments that may help preserve vision.

• #30 Macular Degeneration Therapies & Treatments – Ophthalmology | UCLA Health

  https://www.uclahealth.org/medical-services/ophthalmology/surgical-treatments/macular-degeneration-therapies

  Intraocular anti-VEGF injection therapies have revolutionized the treatment of wet age-related macular degeneration. Wet macular degeneration is the result of the formation of new, fragile and leaky blood vessels growing under the retina, damaging the rod and cone cells. The anti-VEGF drugs, which are injected into the eye with a fine needle, inhibit the growth of these leaky blood vessels and improve vision for patients with wet age-related macular degeneration. […] Laser photocoagulation is the standard therapy for patients with the wet form of age-related macular degeneration (AMD). The procedure uses a highly focused beam of light to seal the leaking blood vessels that damage the macula. Laser photocoagulation is most effective in the early stages of wet AMD. It cannot regain lost vision but it can slow the rate of vision loss from this fast moving form of AMD. […] Clinical researchers are investigating a range of therapeutic options to treat the wet form of AMD.

• #31 Wet AMD Treatment

  https://www.webmd.com/eye-health/macular-degeneration/wet-amd-treatments

  Although theres no cure for wet macular degeneration, treatments can slow the disease and prevent your eyesight from getting worse. […] Several treatments are available for this type. […] Your doctor will most likely recommend injections of anti-VEGF medicine for your wet AMD. […] Because wet AMD is a problem of abnormal blood vessels, doctors can treat it with drugs that block VEGF. […] One of the medications you can get for wet AMD, ranibizumab, also comes as an implant called Susvimo. […] This wet AMD treatment uses medicine that reacts to certain types of light and a laser to activate that medicine. […] Photodynamic therapy cant restore vision youve already lost. But it may slow down any damage thats happening to your central vision. […] Doctors rarely recommend this treatment, which is also called laser photocoagulation, for wet AMD. The goal is the same as photodynamic therapy to seal off leaking blood vessels.

• #32 Macular Degeneration Treatment | BrightFocus Foundation

  https://www.brightfocus.org/macular/treatments/

  Laser photocoagulation surgery was the first treatment used for wet macular degeneration, but it is only an option for a small number of patients. […] In 2024, the Valeda Light Delivery System was approved for use in dry AMD. Valeda uses multiple wavelengths of light (red and near-infrared) to stimulate cellular processes within the retina, including mitochondrial activity, which can help reduce inflammation and promote healthy cell function.

• #33 Macular Degeneration, Age Related Macular Degeneration

  https://www.willseye.org/disease-macular-degeneration/

  Wills Eye retina doctors are leading experts in the treatment of macular degeneration with the latest clinical trials and new therapeutic approaches for AMD. […] In the past, laser-based therapies were used to target the abnormal blood vessels that cause wet AMD. However, the laser burns typically resulted in scarring and damage to central vision. Fortunately, there are now anti-vascular endothelial growth factor (anti-VEGF) medications available for the treatment of wet AMD. These medications, injected into the eye as an office-based procedure, are currently the preferred therapy for wet AMD due to their unprecedented efficacy. They represent the first therapy that has ever been clinically proven to help improve vision in a substantial proportion of patients with wet AMD. Timing is important, as earlier identification and treatment of wet AMD is associated with better visual outcomes. […] Wills Eye Retina specialists are in the forefront of research efforts, participating in multiple clinical trials to investigate new forms of treatment for macular degeneration and a variety of other retinal conditions.

• #34 Emerging treatments for wet age-related macular degeneration – PubMed

  https://pubmed.ncbi.nlm.nih.gov/24555421/

  Wet or exudative age-related macular degeneration (AMD) is the leading cause of blindness in the United States for individuals over the age of 65 years. Wet AMD is characterized by the formation of choroidal neovascularization, which can lead to edema, hemorrhage and scarring of the macula. This leads to metamorphopsia and vision loss. Without treatment, the loss of vision is permanent. The current gold standard treatment of wet AMD consists of intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications. […] Numerous new therapies in the drug pipeline aim at addressing limitations of current treatments. Future therapies involve novel compounds that attack different parts of the VEGF cascade, novel delivery systems aimed at reducing the frequency of intraocular injections, combination therapies and the use of radiation in conjunction with intravitreal therapies.

• #35 Wet Macular Degeneration Prognosis: Outlook and More

  https://www.healthline.com/health/eye-health/wet-amd-treatments-outlook-and-more

  Without treatment, wet AMD causes rapid, progressive central vision loss. It’s important to seek early, sustained treatment to save as much of your vision as possible. […] Ongoing research aims to increase treatment effectiveness for wet AMD. Areas of investigation include gene therapy to help your eyes make their own anti-VEGF medication.

• #36 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  The second is if the blood vessels that are causing the damage have been successfully suppressed and they are no longer leaking onto the macula. […] On rare occasions some people may be offered laser treatment. A light-sensitive drug is injected into the arm. The drug travels to the eye where it is activated by a laser beam, shutting down the abnormal blood vessels. […] Researchers all over the world are working hard to find new and improved treatments for AMD. […] One area that is being highly researched is the development of longer acting drugs for wet AMD. Longer acting treatments would allow patients to have fewer injections and trips to the eye clinic, and we are starting to see these new drugs become available. […] Another way of reducing injections is an implant containing a drug reservoir. The implant is filled with an anti-VEGF drug and inserted into the eye. It then slowly releases the drug over the course of a few months, and will only need refilling every six to nine months. […] Gene therapy is another approach being researched to reduce the need for injections.

• #37 What are the treatment options for wet macular degeneration?

  https://www.medicalnewstoday.com/articles/wet-macular-degeneration-treatment

  Wet macular degeneration is an eye disease that can lead to central vision loss. However, there are treatments to help slow vision loss, including injectable medications and laser surgery. […] Wet AMD occurs when atypical blood vessels grow behind the retina in the eye. […] There are several effective treatments available for wet AMD that may slow or stop a complete loss of central vision. […] The most common treatment for wet AMD is anti-VEGF injections. […] Anti-VEGF injections can block VEGF proteins and stop any further damage. A person may also see some improvement in their vision. […] Photodynamic therapy (PDT) is another form of treatment for wet AMD. […] Clinical human trials are currently taking place on gene therapy for the treatment of wet AMD. […] There is now a type of monoclonal antibody that received Food and Drug Administration (FDA) approval in 2022 for the treatment of wet AMD. […] In October 2021, the FDA gave approval for the Susvimo implant in the treatment of wet AMD. […] There are several treatments available for wet AMD, including eye injections, laser therapy, gene therapies, and more.

• #38 Experimental gene therapy for wet age-related macular degeneration offers promise for older adults

  https://health.ucdavis.edu/news/headlines/experimental-gene-therapy-for-wet-age-related-macular-degeneration-offers-promise-for-older-adults/2024/01

  Wet age-related macular degeneration, or AMD, affects approximately 2 million people in the United States, Europe and Japan. It is a leading cause of vision loss among older adults. A new gene therapy being tested at UC Davis Health may offer a better treatment option. […] Ophthalmologists at UC Davis Health used an experimental gene therapy last summer to treat a patient with wet AMD. It was the first time the UC Davis Eye Center had used gene therapy. […] If approved, a gene therapy solution has the potential to maintain vision while reducing the number of injections by allowing the eye to continuously produce the medicine on its own, Yiu said. […] The treatment was part of a randomized, partially masked, controlled, phase 3 clinical study evaluating the efficacy and safety of an experimental therapy, ABBV-RGX-314, for wet AMD.

• #39 Gene Therapy for Wet Age-related Macular Degeneration | Retinal Physician

  https://www.retinalphysician.com/issues/2024/april/gene-therapy-for-wet-age-related-macular-degeneration/

  Age-related macular degeneration (AMD) is the fourth leading cause of blindness in older adults and is estimated to affect 8.7% of the global population. The neovascular, or exudative (wet), form of the disease currently requires long-term treatment with intravitreal antivascular endothelial growth factor (VEGF) pharmacotherapy, resulting in a high treatment and office visit burden experienced by patients and their caregivers. […] Accordingly, several gene therapies are being explored in clinical testing as potential options to help mitigate the need for frequent injections and potentially curb long-term costs associated with chronic intravitreal injection (IVI) therapy. […] Recently, there have been several promising updates from clinical trial programs exploring the role of various gene therapies in nAMD.

• #40 Gene Therapy for Wet Age-related Macular Degeneration | Retinal Physician

  https://www.retinalphysician.com/issues/2024/april/gene-therapy-for-wet-age-related-macular-degeneration/

  Gene therapy research in ophthalmology is exploring 3 potential delivery routes for treatment of nAMD, which have different considerations regarding safety and efficacy. […] The subretinal approach via the transvitreal route directly delivers vectors to the retinal pigmented epithelial and retinal layer, a space considered more immune privileged than the vitreous, with mechanisms significantly reducing inflammation risk. […] Lastly, the suprachoroidal injection approach delivers the gene therapy payload via the potential space between the sclera and the choroid (suprachoroidal space, or SCS). […] ADVM-022 (Adverum Biotechnologies), now known as Ixo-vec (ixoberogene soroparvovec), is a potential in-office intravitreal gene therapy treatment option for nAMD. […] The 3-year outcomes for the treatment have been reported from the phase 1 dose-escalation OPTIC trial, which included 2 treatment arms: 2×10 vg (vector genomes) and 6×10 vg.

• #41 Transformative treatment for wet, age-related macular degeneration | VCH Research Institute

  https://www.vchri.ca/stories/2023/10/23/transformative-treatment-wet-age-related-macular-degeneration

  „With the patient’s own retinas producing the drug, this therapy has the potential to significantly reduce the need for eye injections,” explains Navajas. […] In preliminary studies, some wet AMD patients have not required an injection for up to five years while maintaining their vision. […] If Navajas’s innovative gene therapy trial succeeds, the therapy he and his team are testing could potentially be integrated into clinical practice in support of greater patient comfort and quality of life while simultaneously enabling health care resources to be redirected to other urgent care needs.

• #42 A new target for treatment of one type of macular degeneration

  https://news.osu.edu/a-new-target-for-treatment-of-one-type-of-macular-degeneration/

  A new study in mice hints at the promise of an eventual alternative treatment option for the wet version of age-related macular degeneration (AMD). […] The only current treatment for wet AMD is injection into the eye of a medication that blocks the activity of a growth factor protein, called VEGF, which is also known to prompt formation of abnormal blood vessel growth in this condition. […] Anti-VEGF treatment has shortcomings after two years, about half of people stop responding. […] The team then tested the effects of an experimental compound that inhibits telomerase activity. They confirmed that the drug lowered telomerase activity in healthy mice, and found that injecting it into the eyes of mice with symptoms mimicking wet AMD significantly reduced the abnormal blood vessel invasion.

• #43 A new target for treatment of one type of macular degeneration

  https://news.osu.edu/a-new-target-for-treatment-of-one-type-of-macular-degeneration/

  The experimental treatments effectiveness at curbing abnormal blood vessel growth in mice was similar to the current anti-VEGF treatment, Kerur said. […] Possibly, one goal would be using a combination therapy rather than one alone, Kerur said. But telomerase inhibition by itself can also be pursued independently, and that is the plan.

• #44 Best Treatments for Wet Macular Degeneration | Advanced Sight Center

  https://www.advancedsightcenter.com/2024/11/01/best-treatments-for-wet-macular-degeneration/

  Laser therapy is a less common treatment for wet macular degeneration. […] While nutritional supplements cannot cure wet macular degeneration, they can help support overall eye health. […] The best treatment for wet macular degeneration often depends on the individual patient’s condition and medical history. […] Regular follow-ups and monitoring are essential to adjust the treatment as needed and ensure optimal results of wet macular degeneration treatment. […] Wet macular degeneration can be a daunting diagnosis, but with the right treatment and support, you can manage this condition effectively. […] From medical treatments like anti-VEGF injections and photodynamic therapy to lifestyle changes and nutritional supplements, there are many ways to protect your vision and improve your quality of life. […] If you or someone you know is dealing with wet macular degeneration, don’t hesitate to seek professional help. […] Our board-certified ophthalmologist and optometrist will work with you to create a personalized wet macular degeneration treatment plan and help you maintain your eye health.

• #45 Wet Macular Degeneration | Signs, Symptoms, and Treatments

  https://www.macular.org/about-macular-degeneration/wet-macular-degeneration

  Current treatment options target controlling bleeding, with the accepted first line of treatment being Anti-VEGF drugs that control bleeding by stopping the growth of new blood vessels that tend to be leaky. […] Anti-VEGF drugs do not restore vision, though some patients may experience a sense of vision restoration due to the body reabsorbing fluid behind the retina after the bleeding is stopped. […] But anti-VEGF drugs cannot repair retinal scarring, which is the main culprit of vision loss in wet macular degeneration. […] The earlier the intervention, the more vision you will be able to preserve.

• #46 Treatment for Wet Age-Related Macular Degeneration

  https://www.webmd.com/eye-health/macular-degeneration/video/treat-wet-amd

  Treating your wet AMD can help slow down or prevent vision loss. […] Early treatment for wet AMD may help you see better for longer.

• #47 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  New forms of anti-VEGF drugs are now available to treat wet AMD, called biosimilars. The first to become available is Ongavia, a biosimilar to ranibizumab. […] A biosimilar is a medicine developed to be highly similar to an existing biological medicine. Biosimilars might vary slightly from the original brand of medicine, but they work in the same way and they are equally safe and effective. […] Injections do not work if there is already longstanding damage to the macula. Around one in 10 people with wet AMD do not respond to treatment. […] There are two main reasons why patients who previously responded well to treatment may stop injections. The first is if someones macular has too much damage caused by the condition. This means a person has lost the majority of their central vision in that eye and therefore injections are no longer effective and it is in the patients best interest that treatment is stopped.

• #48 A new target for treatment of one type of macular degeneration

  https://news.osu.edu/a-new-target-for-treatment-of-one-type-of-macular-degeneration/

  A new study in mice hints at the promise of an eventual alternative treatment option for the wet version of age-related macular degeneration (AMD). […] The only current treatment for wet AMD is injection into the eye of a medication that blocks the activity of a growth factor protein, called VEGF, which is also known to prompt formation of abnormal blood vessel growth in this condition. […] Anti-VEGF treatment has shortcomings after two years, about half of people stop responding. […] The team then tested the effects of an experimental compound that inhibits telomerase activity. They confirmed that the drug lowered telomerase activity in healthy mice, and found that injecting it into the eyes of mice with symptoms mimicking wet AMD significantly reduced the abnormal blood vessel invasion.

• #49 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden

  https://www.ajmc.com/view/wet-agerelated-macular-degeneration-treatment-advances-to-reduce-the-injection-burden

  AMD-attributed blindness has dropped by approximately 50% to 70% since anti-vascular endothelial growth factor (anti-VEGF) medications were introduced 15 years ago. However, anti-VEGF agents may suppress disease neovascular AMD activity just temporarily, and the progression of AMD can be relentless. Patients with neovascular AMD may require monthly clinic visits for costly intravitreal injections for a decade or longer. […] In randomized clinical trials, visual acuity on an eye chart was maintained within 3 lines of baseline in 95% or more of patients after 2 years of anti-VEGF injections. Unfortunately, these vision gains were often not maintained after leaving the protocol-driven clinical trial environment. Vision preservation in the real world appears to fall short of these clinical trial results, with indications that patients receive fewer anti-VEGF injections and less frequent monitoring than recommended.

• #50 Medication for Macular Degeneration | NYU Langone Health

  https://nyulangone.org/conditions/macular-degeneration/treatments/medication-for-macular-degeneration

  Although there are currently no medications available to manage dry macular degeneration, NYU Langone ophthalmologists can prescribe medications to help prevent the wet form of macular degeneration from progressing. […] These medications are given as intravitreal injections, which means they are injected into the eye. They are so effective that in many people some vision can be restored after consistent treatment. […] In wet macular degeneration, abnormal blood vessels grow underneath the macula, the part of the eyes retina that enables you to see objects directly in front of you. […] However, if medication helps the blood vessels stop leaking, the progression of the disease may be halted. […] A new class of medications, known as anti-vascular endothelial growth factor therapy, is very effective in stopping the growth of new abnormal blood vessels in the eye. […] In most people who are given anti-vascular endothelial growth factor therapy, wet macular degeneration stops progressing. Vision loss is halted in about 90 percent of people, and up to one-third experience improvements in vision after treatment is complete.

• #51 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden

  https://www.ajmc.com/view/wet-agerelated-macular-degeneration-treatment-advances-to-reduce-the-injection-burden

  AMD-attributed blindness has dropped by approximately 50% to 70% since anti-vascular endothelial growth factor (anti-VEGF) medications were introduced 15 years ago. However, anti-VEGF agents may suppress disease neovascular AMD activity just temporarily, and the progression of AMD can be relentless. Patients with neovascular AMD may require monthly clinic visits for costly intravitreal injections for a decade or longer. […] In randomized clinical trials, visual acuity on an eye chart was maintained within 3 lines of baseline in 95% or more of patients after 2 years of anti-VEGF injections. Unfortunately, these vision gains were often not maintained after leaving the protocol-driven clinical trial environment. Vision preservation in the real world appears to fall short of these clinical trial results, with indications that patients receive fewer anti-VEGF injections and less frequent monitoring than recommended.

• #52 Wet macular degeneration – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113

  Macular degeneration, wet care at Mayo Clinic […] To diagnose wet macular degeneration, an eye doctor typically reviews medical and family history and does a complete eye exam. […] Treatments are available that may help slow disease progression and preserve existing vision. If started early enough, treatment may recover some lost vision. […] Some medicines, called anti-VEGF drugs, may help stop the growth of new blood vessels. These medicines block the effects of growth signals the body sends to generate new blood vessels. They are considered the first line of treatment for all stages of wet macular degeneration. […] An eye doctor injects these medicines into the affected eye. Shots may be needed every 4 to 6 weeks to maintain the beneficial effect of the medicine. In some instances, vision may be partially recovered as the blood vessels shrink and the body absorbs the fluid under the retina.

• #53 Wet Macular Degeneration | Signs, Symptoms, and Treatments

  https://www.macular.org/about-macular-degeneration/wet-macular-degeneration

  Current treatment options target controlling bleeding, with the accepted first line of treatment being Anti-VEGF drugs that control bleeding by stopping the growth of new blood vessels that tend to be leaky. […] Anti-VEGF drugs do not restore vision, though some patients may experience a sense of vision restoration due to the body reabsorbing fluid behind the retina after the bleeding is stopped. […] But anti-VEGF drugs cannot repair retinal scarring, which is the main culprit of vision loss in wet macular degeneration. […] The earlier the intervention, the more vision you will be able to preserve.

• #54 Macular Degeneration: Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/15246-macular-degeneration

  During photodynamic therapy (PDT), your eye care specialist uses a combination of an injectable light-sensitive drug and a laser to destroy extra blood vessels in your eye. […] During this treatment, your provider will use a laser to seal and destroy the leaking blood vessels. […] Treatments for wet AMD carry some risk of complications, including: Eye infection, Retinal detachment, Structural eye damage, Faster onset of cataracts, Severe vision loss. […] Age-related macular degeneration (AMD) is the leading cause of vision loss in older adults. […] Wet macular degeneration can cause rapid vision loss and may lead to legal blindness. Your eye care provider can offer treatments that may help preserve vision.

• #55 Macular Degeneration: Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/15246-macular-degeneration

  During photodynamic therapy (PDT), your eye care specialist uses a combination of an injectable light-sensitive drug and a laser to destroy extra blood vessels in your eye. […] During this treatment, your provider will use a laser to seal and destroy the leaking blood vessels. […] Treatments for wet AMD carry some risk of complications, including: Eye infection, Retinal detachment, Structural eye damage, Faster onset of cataracts, Severe vision loss. […] Age-related macular degeneration (AMD) is the leading cause of vision loss in older adults. […] Wet macular degeneration can cause rapid vision loss and may lead to legal blindness. Your eye care provider can offer treatments that may help preserve vision.

• #56 Treatments for Patients with Wet Age-Related Macular Degeneration | Hull University Teaching Hospitals NHS Trust

  https://www.hey.nhs.uk/patient-leaflet/treatments-patients-wet-age-related-macular-degeneration/

  The chances of a good result with PDT are lower than with anti VEGF injections. In particular only 5% of patients treated with PDT have a big increase in vision compared to 30 to 40% treated with injections. Hence anti VEGF injections have become the standard treatment for all forms of Wet AMD. […] Like all medicines, anti-VEGF treatment can cause side effects, although not everybody gets them. The side effects are either from the medicine itself or from the injection procedure. Most of the side-effects involve the eye alone. […] Regardless of the drug is used, each injection procedure carries a small risk (1:1000) of serious complication including infection inside the eyeball (endophthalmitis) which can potentially result in total loss of vision if not treated promptly. […] There are no proven risks to your general health with this course of injections.

• #57 Emerging treatments for wet age-related macular degeneration – PubMed

  https://pubmed.ncbi.nlm.nih.gov/24555421/

  Limitations of current treatments include the need for repeated injections, the high financial costs and treatment burdens of repeated injections, the risk of adverse ocular and systemic adverse events, and the inability to completely reverse the disease process of wet AMD. There are many new therapies and approaches in the pipeline which hold promise for improving the treatment of wet AMD.

• #58 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  New forms of anti-VEGF drugs are now available to treat wet AMD, called biosimilars. The first to become available is Ongavia, a biosimilar to ranibizumab. […] A biosimilar is a medicine developed to be highly similar to an existing biological medicine. Biosimilars might vary slightly from the original brand of medicine, but they work in the same way and they are equally safe and effective. […] Injections do not work if there is already longstanding damage to the macula. Around one in 10 people with wet AMD do not respond to treatment. […] There are two main reasons why patients who previously responded well to treatment may stop injections. The first is if someones macular has too much damage caused by the condition. This means a person has lost the majority of their central vision in that eye and therefore injections are no longer effective and it is in the patients best interest that treatment is stopped.

• #59 Treatments for Patients with Wet Age-Related Macular Degeneration | Hull University Teaching Hospitals NHS Trust

  https://www.hey.nhs.uk/patient-leaflet/treatments-patients-wet-age-related-macular-degeneration/

  For some patients the risks of treatment will outweigh the benefits and for others the eye may be too badly affected to make treatment worthwhile. […] Some patients with Wet AMD have a particular pattern of blood vessels growing beneath the retina, which may remain stable without treatment. In this case it is advisable to wait before commencing injection treatment for a short period of monitoring to confirm if the disease is progressing or not. […] Current NHS (NICE) guidance is that patients with very good vision should be monitored initially and only treated if the vision starts to deteriorate in view of the small risk involved with the treatment.

• #60 Macular disease treatments – Macular Society

  https://www.macularsociety.org/diagnosis-treatment/treatments/

  New forms of anti-VEGF drugs are now available to treat wet AMD, called biosimilars. The first to become available is Ongavia, a biosimilar to ranibizumab. […] A biosimilar is a medicine developed to be highly similar to an existing biological medicine. Biosimilars might vary slightly from the original brand of medicine, but they work in the same way and they are equally safe and effective. […] Injections do not work if there is already longstanding damage to the macula. Around one in 10 people with wet AMD do not respond to treatment. […] There are two main reasons why patients who previously responded well to treatment may stop injections. The first is if someones macular has too much damage caused by the condition. This means a person has lost the majority of their central vision in that eye and therefore injections are no longer effective and it is in the patients best interest that treatment is stopped.

• #61 Treatments for Patients with Wet Age-Related Macular Degeneration | Hull University Teaching Hospitals NHS Trust

  https://www.hey.nhs.uk/patient-leaflet/treatments-patients-wet-age-related-macular-degeneration/

  For some patients the risks of treatment will outweigh the benefits and for others the eye may be too badly affected to make treatment worthwhile. […] Some patients with Wet AMD have a particular pattern of blood vessels growing beneath the retina, which may remain stable without treatment. In this case it is advisable to wait before commencing injection treatment for a short period of monitoring to confirm if the disease is progressing or not. […] Current NHS (NICE) guidance is that patients with very good vision should be monitored initially and only treated if the vision starts to deteriorate in view of the small risk involved with the treatment.

• #62 Treatments for Patients with Wet Age-Related Macular Degeneration | Hull University Teaching Hospitals NHS Trust

  https://www.hey.nhs.uk/patient-leaflet/treatments-patients-wet-age-related-macular-degeneration/

  For some patients the risks of treatment will outweigh the benefits and for others the eye may be too badly affected to make treatment worthwhile. […] Some patients with Wet AMD have a particular pattern of blood vessels growing beneath the retina, which may remain stable without treatment. In this case it is advisable to wait before commencing injection treatment for a short period of monitoring to confirm if the disease is progressing or not. […] Current NHS (NICE) guidance is that patients with very good vision should be monitored initially and only treated if the vision starts to deteriorate in view of the small risk involved with the treatment.

• #63 What is Wet Macular Degeneration? Signs, Causes, and Management | eyecarecenter

  https://www.eyecarecenter.com/eye-care-resources/what-is-wet-macular-degeneration

  Adopting certain lifestyle changes and supportive therapies can significantly aid in managing macular degeneration. A diet rich in leafy greens, fruits, and fish provides vital nutrients essential for eye health. Regular physical activity enhances blood circulation, which is beneficial for overall health. For patients, AREDs2 vitamin supplementation can be beneficial. Additionally, quitting smoking can slow the progression of the disease. Employing low vision aids such as magnifying glasses, special lenses, and electronic reading devices can also help maintain independence and improve the quality of life for those affected by this condition.

• #64 Age-related macular degeneration: Early detection and timely treatment may help preserve vision – Harvard Health

  https://www.health.harvard.edu/blog/age-related-macular-degeneration-early-detection-and-timely-treatment-may-help-preserve-vision-2020112421362

  Age-related macular degeneration (ARMD) is the leading cause of blindness in adults over the age of 60. […] If you have ARMD, understanding the signs and symptoms, proper monitoring, early detection of advancing disease, and timely treatment are all key to preserving vision. […] There are two main types of advanced ARMD: exudative (wet) ARMD and non-exudative (dry). The presence of CNV confers a designation of wet ARMD. […] In people who do develop advanced ARMD, the availability of treatment options depends on whether they have the dry or wet form of the condition. […] However, there are several therapies under investigation that may one day slow down or potentially reverse the changes that impact vision. […] Conversely, wet ARMD has multiple FDA-approved and off-label agents proven to arrest and reverse the effects of CNV in the macula. The current standard of care is injection of anti-vascular endothelial growth factor (anti-VEGF) medications into the vitreous cavity of the eye. […] Current therapies can control the disease and preserve vision for years or longer, so early detection is key. […] Your ophthalmologist will also be most aware of new and emerging treatments in the rapidly evolving landscape of ARMD therapy.

• #65 Wet AMD | Wills Eye Hospital

  https://www.willseye.org/wet-amd/

  Wet age-related macular degeneration (AMD) is a form of eye disease that affects the macula, the central part of the retina responsible for sharp, detailed vision. […] Wills is a national leader in clinical research with the latest clinical trials for new therapeutic approaches for wet AMD. […] While there is still no cure for wet AMD, we currently have a few medications that are very effective in treating this condition. […] Thankfully, there are new treatments available for those with wet AMD. […] Fortunately, there are now anti-vascular endothelial growth factor (anti-VEGF) medications available for the treatment of wet AMD. These medications, injected into the eye as an office-based procedure, are currently the preferred therapy for wet AMD due to their unprecedented efficacy. […] Timing is important, as earlier identification and treatment of wet AMD is associated with better visual outcomes.

• #66 Age-Related Macular Degeneration—Dry and Wet – Retina Group of New England

  https://retinagroupofnewengland.com/conditions-we-treat/age-related-macular-degeneration-dry-and-wet/

  Age-related Macular Degeneration (AMD) is the major cause of severe vision loss in individuals over the age of 60. While there is currently no cure, the progression of the disease can in some cases be slowed or reversed. […] There are two forms of macular degeneration: dry (atrophic) and wet (neovascular). Approximately 85-95% of people with macular degeneration have the dry form. […] The dry form of AMD can convert to the wet form, which is much more severe. It is very important that individuals with dry AMD monitor vision daily with an Amsler grid and report any changes to their eye doctor. […] In the wet form of AMD, abnormal blood vessels grow under the macula and leak fluid and blood. […] We count with all current treatment drugs and therapies. An injection of an anti-vascular endothelial growth factor (anti-VEGF) in the eye can seal these vessels and slow vision loss. It may even restore some vision. Anti-VEGF injections include Lucentis (Ranibizumab, made by Genentech/Novartis), off-label Avastin (Bevacizumab from Genentech) and Eylea (Aflibercept, VEGF Trap-Eye from Regeneron/Bayer) are currently used with great success. Newer drugs are always being investigated to improve these positive outcomes even further.

• #67 What is Wet Macular Degeneration? Signs, Causes, and Management | eyecarecenter

  https://www.eyecarecenter.com/eye-care-resources/what-is-wet-macular-degeneration

  Adopting certain lifestyle changes and supportive therapies can significantly aid in managing macular degeneration. A diet rich in leafy greens, fruits, and fish provides vital nutrients essential for eye health. Regular physical activity enhances blood circulation, which is beneficial for overall health. For patients, AREDs2 vitamin supplementation can be beneficial. Additionally, quitting smoking can slow the progression of the disease. Employing low vision aids such as magnifying glasses, special lenses, and electronic reading devices can also help maintain independence and improve the quality of life for those affected by this condition.

• #68 What is Macular Degeneration?

  https://www.wolfeeyeclinic.com/medical-services/retina-disease/macular-degeneration

  If you develop wet AMD you will need treatment from a retina or macular degeneration specialist to prevent you from permanently losing vision. […] While there is no cure for age-related macular degeneration, there are things that you can do to decrease the risk of vision loss and prevent the AMD from worsening. […] The National Eye Institutes Age-Related Eye Disease Study (AREDS) found that taking a specific high-dose formulation of antioxidants and zinc in addition to a regular multivitamin can reduce the risk of progression of dry AMD in some patients. […] AREDS vitamin supplements are currently the only recommended treatment for dry AMD. […] Wet AMD is most often treated with intravitreal injections of medicine into the eye. […] The goal of the treatment is to keep the wet AMD under control with the least amount of treatment possible.

• #69 Wet macular degeneration – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113

  Photodynamic therapy. This procedure is a possible treatment for the irregular blood vessel growth in wet macular degeneration. However, it is much less common than treatment with anti-VEGF shots. […] Photodynamic therapy may improve vision and reduce the rate of vision loss. Repeated treatments may be needed over time, as the treated blood vessels may reopen. […] Photocoagulation. During photocoagulation therapy, an eye doctor uses a high-energy laser beam to seal problem blood vessels under the macula. This procedure helps stop the vessels from bleeding, with the aim of minimizing further damage to the macula. […] Low vision rehabilitation. Age-related macular degeneration doesn’t affect side vision and typically doesn’t cause total blindness. But it can reduce or eliminate central vision. You need central vision to read, drive and recognize people’s faces. […] Macular degeneration, wet care at Mayo Clinic […] Treatments for wet macular degeneration […] Photodynamic therapy.

• #70 Wet AMD | Wills Eye Hospital

  https://www.willseye.org/wet-amd/

  Photodynamic Therapy (PDT) with Visudyne is another treatment for wet AMD. […] PDT does not improve vision and is rarely used. […] In uncommon, specific cases of choroidal neovascularization where the abnormal blood vessels are not beneath the center of the macula, laser photocoagulation may be used. […] Low vision aides may help improve the quality of life for people whose vision is impaired to the point that they cannot carry out important visual activities of daily living such as reading mail or writing checks. […] In July 2010, an implantable miniature telescope was FDA approved for select patients with advanced end-stage macular degeneration in both eyes.

• #71 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden

  https://www.ajmc.com/view/wet-agerelated-macular-degeneration-treatment-advances-to-reduce-the-injection-burden

  The goals of anti-VEGF therapy in neovascular AMD are to achieve excellent functional visual acuity and maintain a dry macula on clinical and OCT examination. This may require an individualized approach because AMD is a heterogenous disease. […] Two approaches—treat-and-extend (TE) and pro re nata (PRN; as needed)—have been used to reduce the injection burden in stable, nonexudative patients with neovascular AMD. The TE regimen gradually extends the dosing interval in 2-week increments to a maximum interval of 12 to 16 weeks. If disease activity is observed, then the treatment interval is reduced, often in 2-week increments but this varies with patient treatment factors. […] A robust pipeline of investigational drugs for neovascular AMD is expected to extend the dosing interval beyond that of currently available agents. Agents that are expected to reach the market within the next 3 years include abicipar pegol and faricimab, as well as the ranibizumab port system for extended-release drug delivery. […] Gene therapy could be another option for addressing the anti-VEGF injection burden. Initial clinical data for gene therapy have generated cautious excitement about its potential to substantially reduce the treatment burden in neovascular AMD. The technology uses a viral vector to insert the DNA coding sequence for an anti-VEGF agent into retinal cells that then act like anti-VEGF factories.

• #72 Wet Macular Degeneration Prognosis: Outlook and More

  https://www.healthline.com/health/eye-health/wet-amd-treatments-outlook-and-more

  Without treatment, wet AMD causes rapid, progressive central vision loss. It’s important to seek early, sustained treatment to save as much of your vision as possible. […] Ongoing research aims to increase treatment effectiveness for wet AMD. Areas of investigation include gene therapy to help your eyes make their own anti-VEGF medication.

Zobacz więcej